Brief: FDA Approves First In Class Targeted Therapy For Metastatic Pancreatic Cancer
26/08/2026 16:34
BRIEF-FDA Approves First In Class Targeted Therapy For Metastatic Pancreatic Cancer Aug 26 (Reuters) - US FDA:
FDA APPROVES FIRST IN CLASS TARGETED THERAPY FOR METASTATIC PANCREATIC CANCER
U.S. FDA : APPROVES RASONQUE (DARAXONRASIB), FIRST-IN-CLASS RAS INHIBITOR FOR METASTATIC PANCREATIC CANCER
Further company coverage: RVMD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revolution Medicines
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
Brief: CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU
Revolution Medicines wins EU committee backing for pancreatic cancer treatment (updated)
EMA recommends approval of Revolution's pancreatic cancer drug
Revolution Medicines falls on pancreatic cancer drug data concerns